AMGEN Inc.

NASDAQ:AMGN   3:59:59 PM EDT
251.39
+1.08 (+0.43%)
4:29:09 PM EDT: $251.38 -0.01 (-0.00%)
Products, Regulatory

Amgen Says Source Phase 3 Trial For Tezepelumab Did Not Meet Primary Endpoint

Published: 12/22/2020 07:14 GMT
AMGEN Inc. (AMGN) - Update on Source Phase 3 Trial for Tezepelumab in Patients With Severe, Oral Corticosteroid-dependent Asthma.
Safety Profile of Tezepelumab in Trial Was Consistent With Previous Trials.
Detailed Results From Source Trial Will Be Presented at a Future Medical Meeting.
Source Trial Did Not Meet Primary Endpoint.
Amgen - Tezepelumab's Effect on Other Efficacy Parameters Was Similar to Those in Previous Studies, Including Registrational Phase 3 Navigator Study.